410 related articles for article (PubMed ID: 12771733)
1. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
Mosharafa AA; Foster RS; Leibovich BC; Bihrle R; Johnson C; Donohue JP
J Urol; 2003 Jun; 169(6):2126-8. PubMed ID: 12771733
[TBL] [Abstract][Full Text] [Related]
2. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
3. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
[TBL] [Abstract][Full Text] [Related]
4. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer.
Coogan CL; Hejase MJ; Wahle GR; Foster RS; Rowland RG; Bihrle R; Donohue JP
J Urol; 1996 Nov; 156(5):1656-8. PubMed ID: 8863564
[TBL] [Abstract][Full Text] [Related]
5. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
6. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?
Russell CM; Sharma P; Agarwal G; Fisher JS; Richard GJ; Spiess PE; Pow-Sang JM; Poch MA; Sexton WJ
Can J Urol; 2016 Feb; 23(1):8127-34. PubMed ID: 26892052
[TBL] [Abstract][Full Text] [Related]
7. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer.
Mosharafa AA; Foster RS; Koch MO; Bihrle R; Donohue JP
J Urol; 2004 May; 171(5):1839-41. PubMed ID: 15076289
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
10. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
[TBL] [Abstract][Full Text] [Related]
11. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
[TBL] [Abstract][Full Text] [Related]
12. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
13. Retroperitoneal laparoscopic lymph node dissection for staging non-seminomatous germ cell tumors before and after chemotherapy.
Rassweiler JJ; Henkel TO; Stock C; Seemann O; Frede T; Alken P
Lymphology; 1996 Mar; 29(1):36-44. PubMed ID: 8721978
[TBL] [Abstract][Full Text] [Related]
14. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.
Nash PA; Leibovitch I; Foster RS; Bihrle R; Rowland RG; Donohue JP
J Urol; 1998 Mar; 159(3):707-10. PubMed ID: 9474130
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.
Rice KR; Beck SD; Bihrle R; Cary KC; Einhorn LH; Foster RS
J Urol; 2014 Nov; 192(5):1397-402. PubMed ID: 24813309
[TBL] [Abstract][Full Text] [Related]
16. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
17. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer.
Subramanian VS; Nguyen CT; Stephenson AJ; Klein EA
Urol Oncol; 2010; 28(5):504-9. PubMed ID: 19097812
[TBL] [Abstract][Full Text] [Related]
18. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection.
Chang SS; Smith JA; Girasole C; Baumgartner RG; Roth BJ; Cookson MS
J Urol; 2002 Jul; 168(1):87-92. PubMed ID: 12050498
[TBL] [Abstract][Full Text] [Related]
19. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.
Steiner H; Zangerl F; Stöhr B; Granig T; Ho H; Bartsch G; Peschel R
J Urol; 2008 Oct; 180(4):1348-52; discussion 1352-3. PubMed ID: 18707723
[TBL] [Abstract][Full Text] [Related]
20. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection.
Johnston P; Beck SD; Cheng L; Masterson TA; Bihrle R; Kesler K; Foster RS
J Urol; 2013 Sep; 190(3):874-7. PubMed ID: 23517745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
